Dr Martens /£DOCS
1D1W1MYTD1Y5YMAX
Capital at risk
About Dr Martens
Dr. Martens, also known as Docs or DMs, is a United Kingdom-based company renowned for its iconic range of footwear, alongside a variety of clothing and accessories. The company, headquartered in Wollaston, Northamptonshire, operates primarily in the footwear manufacturing sector. Established in 1947, Dr. Martens has grown to become a symbol of self-expression and counterculture, distributing its products worldwide under the Dr. Martens brand.
- Ticker
- £DOCS
- Sector
- Consumer Discretionary
- Primary listing
- LSE
- Employees
- 2,377
- Headquarters
- London, United Kingdom
- Website
- www.drmartensplc.com
Dr Martens Metrics
BasicAdvanced
£622M
27.25
£0.02
0.24
£0.03
3.90%
Price and volume
Market cap
£622M
Beta
0.24
52-week high
£1.01
52-week low
£0.59
Average daily volume
1.5M
Dividend rate
£0.03
Financial strength
Current ratio
2.609
Quick ratio
1.559
Long term debt to equity
0.961
Total debt to equity
1.089
Dividend payout ratio (TTM)
103.36%
Interest coverage (TTM)
2.61%
Profitability
EBITDA (TTM)
85.7
Gross margin (TTM)
66.15%
Net profit margin (TTM)
3.11%
Operating margin (TTM)
9.47%
Effective tax rate (TTM)
27.22%
Revenue per employee (TTM)
£320,000
Management effectiveness
Return on assets (TTM)
5.12%
Return on equity (TTM)
6.54%
Valuation
Price to earnings (TTM)
27.25
Price to revenue (TTM)
0.825
Price to book
1.72
Price to tangible book (TTM)
6.83
Price to free cash flow (TTM)
4.824
Free cash flow yield (TTM)
20.73%
Free cash flow per share (TTM)
0.136
Dividend yield (TTM)
3.90%
Growth
Revenue change (TTM)
-2.88%
Earnings per share change (TTM)
413.26%
3-year revenue growth (CAGR)
-8.56%
10-year revenue growth (CAGR)
12.65%
3-year earnings per share growth (CAGR)
-42.89%
10-year earnings per share growth (CAGR)
7.18%
3-year dividend per share growth (CAGR)
-24.13%
What the Analysts think about Dr Martens
Analyst ratings (Buy, Hold, Sell) for Dr Martens stock.
Analyst projections of the future price of Dr Martens stock.
Bulls say / Bears say
Adjusted pre-tax profit rose 61.3% to £55m, while gross margin improved to 66.2% as Dr Martens reduced discounting and controlled costs. Net debt including leases also fell to £213.5m, showing that the recovery is improving both earnings quality and the balance sheet. (Reuters, MarketScreener)
The US, Dr Martens’ largest market, is showing useful signs of recovery: full-price US direct-to-consumer revenue rose 14% in FY26, and management said July trading was still in line with expectations, with US wholesale particularly encouraging. Stronger wholesale orders could provide operating leverage as the business scales. (Reuters, Dr Martens)
The product offer is becoming less dependent on the classic boot. Shoe revenue grew 19%, new families such as Lowell, Buzz and Zebzag reached 9% of pairs, and management sees further potential in sandals, bags and accessories. (MarketScreener, WWD)
The recovery has not yet produced top-line growth: FY26 revenue fell 2.9% to £764.9m, while EMEA revenue declined 1.7%. Cutting discounts may protect margins, but it also makes the next stage harder because Dr Martens must now grow sales without returning to promotions. (Reuters, MarketScreener)
US tariffs remain a direct cost risk. The FY26 results transcript said tariff-related cash costs included £9.9m, so further trade costs or price increases could either reduce margins or test demand in the company’s most important market. (MarketScreener, AskTraders)
The turnaround still depends on difficult execution rather than a completed recovery. FY27 requires Dr Martens to improve full-price sales in the UK and DACH, launch a new sandals range, upgrade selected retail concepts and unlock operating benefits, while management says European trading remains set against a challenging consumer backdrop. (Dr Martens, MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
Dr Martens Financial Performance
Revenues and expenses
Dr Martens Earnings Performance
Company profitability
Upcoming events
Funds containing Dr Martens
AllGBPEURUSD
Fund name | Fund size | £DOCS weighting |
|---|---|---|
Vanguard FTSE 250£VMID | £1.6B | 0.14% |
iShares FTSE 250£MIDD | £661M | 0.12% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.03% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.